Svein Isungset Støve
Svein Isungset Støve
Academy Leader
Svein Isungset Støve is a researcher at the K. G. Jebsen Center for Parkinson’s Disease (UiB). He has a PhD in Molecular Biology from the University of Bergen with a focus on enzymology, structural biology and drug development. In recent years, his research has focused on the dopaminergic system, particularly how dopamine is produced and stored in synaptic vesicles in dopaminergic neurons, as well as High-Throughput Screening approaches to identify new drugs that can modulate the dopaminergic system. At the K.G. Jebsen Center for Parkinson’s Disease, Svein is leading the scientific efforts to screen for drugs that can screening for drugs that can alter mitochondrial function, with a potential future use in treatment of Parkinson’s Disease.
Position
Researcher at DECODE-PD research group, Nevroklinikken, Haukeland Universitetssykehus and the Biorecognition group, Department of Biomedicine, UiB
Selected Publications
Stove SI, Skjevik ÅA, Teigen K, Martinez A, (2022), Inhibition of vesicular monoamine transporter 2 by β2-adrenergic agonists and the atypical antipsychotic ziprasidone. Commun Biol. 2022 Nov 23;5(1):1283. doi: 10.1038/s42003-022-04121-1.
Støve SI, Flydal MI, Hausvik E, Underhaug J, Martinez A, (2020), Differential scanning fluorimetry in the screening and validation of pharmacological chaperines for soluble and membrane proteins, Book chapter, Chapter 15, Protein Homeostasis Diseases, Elsevier. doi: /10.1016/B978-0-12-819132-3.00015-4
Støve SI, Blenski M, Stray-Pedersen A, Wierenga KJ, Jhangiani SN, Akdemir ZC, Crawford D, McTiernan N, Myklebust LM, Purcarin G, McNall-Knapp R, Wadley A, Belmont JW, Kim JJ, Lupski JR, Arnesen T, (2018), A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy. Eur J Hum Genet. 2018 May 10. doi: 10.1038/s41431-018-0136-0.
Støve SI, Magin R, Foyn H, Marmorstein R, Arnesen T. (2016) Crystal structure of the Golgi-associated human N-alpha acetyltransferase 60 (Naa60/NatF) reveals the molecular determinants for substrate-specific acetylation. Structure, 2016 Jul 6;24(7):1044-56.
Project involvement
Drug Discovery Targeting Mitochondrial Dysfunction in Parkinson’s Disease
Approximately 25% of individuals with idiopathic Parkinson’s Disease exhibit widespread neuronal mitochondrial respiratory dysfunction, which is considered a significant mechanism in the disease’s development. This project aims to restore mitochondrial function in these patients by identifying new drugs that target mitochondrial biogenesis or mitochondrial function. Project leader: Prof. Aurora Martinez, Prof. Charalampos Tzoulis and Svein Isungset Støve
Identification of VMAT2 modulators by cellular screening
Vesicular monoamine transporter 2 (VMAT2) is a membrane transporter protein responsible for packing neurotransmitters such as serotonin and dopamine into synaptic vesicles. This process is vital for neurotransmitter signalling. Inhibitors of VMAT2 are approved for use in treatment of Tardive dyskinesia and Huntington’s Chorea but comes with severe side effects. This project aim to identify novel VMAT2 inhibitors that can treat the same symptoms, but without side effects. Project leader: Svein Isungset Støve.
Structural and Functional Characterization of Vesicular Monoamine Transporter 2
This project aim at achieving a better understanding of the molecular mechanism behind substrate transport by VMAT2. The project invovlves expression and purification of the membrane transporter, Cryo-EM studies and functional assays in cells. Project leader: Svein Isungset Støve. Research collaboration with researchers from CNIO, Madrid, and NCMM in Oslo.